Gufic Biosciences Ltd. Share Price & Stock Analysis

Gufic Biosciences Ltd. (BSE: 509079) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹4,871 Cr, it ranks #845 by market cap among the 6,197 Indian listed companies on FinBizNet, and #27 of 86 in Medicinal Chemicals and Botanical Products. At ₹470.00 (as of 16 Nov 2026), the share price is 4.8% below its 52-week high of ₹493.95 and 75.4% above its 52-week low of ₹268.00. The share price is up 41.6% over one year and up 9.9% over three months.

Key Metrics

Current Price₹470.00
Market Cap₹4,871 Cr
BSE Code509079
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio76.4
Return on Equity10.14%
Return on Assets6.00%
52-Week Range₹268.00 – ₹493.95
1-Year Price Change+41.6%
3-Month Price Change+9.9%
Beta (1Y)0.07
Dividend Yield0.02%
HeadquartersMumbai, Maharashtra
Websitewww.gufic.com

Latest Quarterly Results — Q2 FY27

Revenue₹288 Cr
Net Profit₹23 Cr
Net Margin8.1%
EPS (Basic)₹2.34
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Gufic Biosciences Ltd. Quarterly Revenue and Profit Trend

Gufic Biosciences Ltd. reported revenue of ₹288 Cr in Q2 FY27, up 21.6% from ₹237 Cr in Q2 FY26 and up 10.5% from ₹261 Cr in Q1 FY27. It posted a net profit of ₹23 Cr for the quarter, against a net profit of ₹17 Cr in Q2 FY26 (up 39.5%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹205 Cr (Q4 FY25) to ₹288 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹288 Cr₹23 Cr8.1%
Q1 FY27₹261 Cr₹22 Cr8.6%
Q4 FY26₹252 Cr₹22 Cr8.7%
Q3 FY26₹231 Cr₹12 Cr5.4%
Q2 FY26₹237 Cr₹17 Cr7.1%
Q1 FY26₹224 Cr₹13 Cr5.8%
Q4 FY25₹205 Cr₹8 Cr3.8%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 72.50% of Gufic Biosciences Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 52.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Gufic Biosciences Ltd.

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.

Products and Services

1. Pharmaceutical and Related Products-This segment engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. 2. Pharma-This segment manufactures and trades in tablets, capsules, ointment, syrups/suspension products, powders, injections and lotions, etc. 3. Bulk Drug-This segment manufactures medicinal chemicals. 4. Unallocable Overheads-0

Business Segments

1. Pharmaceutical and Related Products-100%

Gufic Biosciences Ltd. vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Gufic Biosciences Ltd.₹4,871 Cr76.410.14%₹288 Cr+41.6%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Gufic Biosciences Ltd.?

Gufic Biosciences Ltd. is trading at ₹470.00, with a market capitalisation of ₹4,871 Cr.

Which sector does Gufic Biosciences Ltd. belong to?

Gufic Biosciences Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Gufic Biosciences Ltd.?

Gufic Biosciences Ltd. has a P/E of 76.4 and a return on equity of 10.14%.

What is the stock symbol of Gufic Biosciences Ltd.?

Gufic Biosciences Ltd. is listed on the BSE under the scrip code 509079.

How has Gufic Biosciences Ltd.'s share price moved over the past year?

Gufic Biosciences Ltd.'s share price is up 41.6% over one year and up 9.9% over three months. Its 52-week range is ₹268.00 to ₹493.95.

What were Gufic Biosciences Ltd.'s latest quarterly results?

In Q2 FY27, Gufic Biosciences Ltd. reported revenue of ₹288 Cr and net profit of ₹23 Cr, with basic EPS of ₹2.34 (consolidated, parsed from the company's exchange filing).

How have Gufic Biosciences Ltd.'s revenue and profit changed over the past year?

Gufic Biosciences Ltd. reported revenue of ₹288 Cr in Q2 FY27, up 21.6% from ₹237 Cr in Q2 FY26 and up 10.5% from ₹261 Cr in Q1 FY27.

What is the promoter holding in Gufic Biosciences Ltd.?

Promoters held 72.50% of Gufic Biosciences Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.